Gw Pharma ADR (GWPH) 95.94 $GWPH
Boston Scientific (BSX) Meets Q2 Earnings Estimate, Views Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 2:03PM CDT
Boston Scientific Corporation (BSX) announced adjusted EPS of 27 cents in the second quarter of 2016, up 22.7% from the year-ago quarter.
BSX: 24.45 (+0.17), GWPH: 95.94 (+1.62), BAX: 48.53 (+0.51), VASC: 46.60 (+0.73)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 130.85 (-0.29), GWPH: 95.94 (+1.62), BAX: 48.53 (+0.51), VASC: 46.60 (+0.73)
NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.45 (+0.17), ZBH: 130.85 (-0.29), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea
CNW Group - Mon Jul 18, 7:30AM CDT
Medical Cannabis' biggest strength continues to be science as research and development drives sector forward with more consumers opting for marijuana over traditional treatment methods. Investors continue to pour millions of dollars into the newest studies and development of Medical Marijuana Applications as more states push towards legalization.
ABT: 45.34 (+0.59), INSY: 16.02 (+0.37), GWPH: 95.94 (+1.62), PFE: 37.31 (+0.42)
Will AmSurg's Merger with Envision Healthcare Drive Growth?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:08PM CDT
AmSurg (AMSG) recently agreed to merge in an all-stock deal with Envision Healthcare to create one of the largest providers of physician services in the U.S.
AMSG: 72.75 (-2.26), BSX: 24.44 (+0.16), EVHC: 23.82 (-0.77), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
Medtronic's IN.PACT Admiral DCB Wins FDA Nod for 150 mm
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 6:22AM CDT
With Medtronic (MDT)being a major player in the medical devices market, surely the FDA approval will accelerate the demand for its peripheral therapy products.
BSX: 24.44 (+0.16), MDT: 88.17 (+0.54), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
Pfizer Publishes Final Data from Atopic Dermatitis Studies
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:10AM CDT
Pfizer (PFE) announced findings from two pivotal phase III studies on crisaborole for the treatment of patients with mild-to-moderate atopic dermatitis.
GWPH: 95.94 (+1.62), PFE: 37.31 (+0.42), SNY: 42.57 (-0.06), REGN: 434.17 (+9.05)
Geron (GERN) Gets Three Patents for Imetelstat in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:02AM CDT
Geron (GERN) announced that it has received three U.S. patents related to its telomerase inhibitor, imetelstat.
JNJ: 125.48 (+0.25), INVA: 13.05 (+0.18), GWPH: 95.94 (+1.62), GERN: 2.71 (+0.03)
MedTech Tailwinds at a Glance: Which Stocks to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:02PM CDT
MedTech Tailwinds at a Glance: Which Stocks to Buy?
ABMD: 119.11 (+1.14), LDRH: 36.98 (-0.02), MDT: 88.17 (+0.54), PAHC: 20.91 (+0.28), MLAB: 115.01 (-0.62), NUVA: 63.39 (+1.19), BSX: 24.44 (+0.16), BABY: 39.29 (-0.04), SNN: 33.16 (-0.13), JNJ: 125.48 (+0.25), DXCM: 92.46 (+0.23), GWPH: 95.94 (+1.62), RMD: 70.03 (+1.15), WOOF: 70.51 (-0.83), ABT: 45.34 (+0.59), VIVO: 19.58 (+0.22), MASI: 53.07 (+0.10), TMO: 159.64 (+0.80), CYH: 12.58 (-0.19), HTWR: 57.93 (-0.01), FEIC: 106.58 (+0.16), ISRG: 695.16 (-0.60), CFMS: 7.00 (+0.03), STE: 71.51 (+0.56), STJ: 83.66 (+0.62), XRAY: 64.20 (+0.16), HOLX: 39.00 (+0.51)
Illumina (ILMN) Rallies on Exact Sciences Buyout Rumor
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:53AM CDT
With this buyout, Illumina (ILMN) will gain control over Cologuard -- a FDA approved non-invasive screening test of Exact Sciences that uses stool DNA technology to detect colorectal cancer.
NXTM: 22.09 (-0.02), GWPH: 95.94 (+1.62), TGTX: 5.77 (-0.14), ILMN: 170.73 (+4.38)
Wall Street Targets Funding Opportunities for Multi-Billion Dollar Cannabis & Legal Marijuana Operations
PR Newswire - Wed Jul 13, 7:45AM CDT
It is estimated that the expense to start a legal marijuana business in the U.S. could cost more than $1Million, according to the Marijuana Business Association. The absence of commercial credit available for the industry in past has opened up opportunities for institutions & private lenders who want to step into the cannabis industry with the average loan estimated at $750,000. Microsoft Corp. (NASDAQ: MSFT) recently became the first major company to announce its participation in the cannabis/marijuana sector, as the computer giant has partnered with Kind Financial, which helps businesses and government agencies track sales of legalized marijuana.
GWPH: 95.94 (+1.62), MSFT: 56.33 (-0.35)
Boston Scientific's Restructuring Plan & Innovation Offer Hope
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:30AM CDT
On Jul 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 24.44 (+0.16), NXTM: 22.09 (-0.02), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
CytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:07AM CDT
CytRx (CYTR) announced unfavorable initial results from a phase III study on aldoxorubicin in patients with relapsed or refractory soft tissue sarcomas.
MACK: 5.86 (+0.06), INVA: 13.05 (+0.18), GWPH: 95.94 (+1.62), CYTR: 0.60 (-0.05)
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Raising $252.0 Million on NASDAQ Global Market
GlobeNewswire - Tue Jul 12, 10:24PM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW" or the "Company"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,800,000 of American Depositary Shares ("ADSs", representing 33,600,000 ordinary shares of GW, at a price to the public of $90.00 per ADS on the NASDAQ Global Market, raising gross proceeds of approximately $252,000,000 (before deducting underwriting discounts, commissions and offering expenses). GW has granted the underwriters a 30-day option to purchase up to an additional 420,000 ADSs at the public offering price less underwriting discounts and commissions. Closing of the offering is expected to occur on July 18, 2016.
GWPH: 95.94 (+1.62), MS: 28.53 (-0.20)
FDA Okays Medtronic's NuVent for Expanded Use in Sinusitis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:17PM CDT
Medtronic's (MDT) NuVent is a unique balloon sinus dilation system, which enables a better view of one's sinus anatomy and the optimal placement of balloons during surgery.
NXTM: 22.09 (-0.02), MDT: 88.17 (+0.54), GWPH: 95.94 (+1.62), TGTX: 5.77 (-0.14)
AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:19AM CDT
AbbVie's (ABBV) ABT-414 has been granted Rare Pediatric Disease Designation in the U.S. for the treatment of pediatric patients with EGFR-amplified DIPG.
INVA: 13.05 (+0.18), GWPH: 95.94 (+1.62), SGEN: 49.12 (+1.06), ABBV: 66.97 (+0.74)
Genomic Health to Offer Epic Science's AR-V7 test, Shares Up
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:28AM CDT
The availability of the AR-V7 serves as a further development to Genomic Health's (GHDX) recently launched Oncotype SEQ Liquid Select, a next-generation, liquid biopsy test.
ICUI: 117.68 (+0.92), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19), GHDX: 30.22 (+1.19)
Walgreen Boots: Q3 a Mixed Bag, Achieves $1B in Synergy
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:09AM CDT
In Jun 2016, Walgreens Boots (WBA) was successful in achieving its target of at least $1 billion in combined net synergies from the Alliance Boots deal in fiscal 2016.
ICUI: 117.68 (+0.92), WBA: 79.25 (unch), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
Why the Earnings Streak Will Continue for GW Pharmaceuticals (GWPH)
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 7:37AM CDT
GW Pharmaceuticals (GWPH) currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
GWPH: 95.94 (+1.62)
Boston Scientific (BSX) Meets Q2 Earnings Estimate, Views Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 2:03PM CDT
Boston Scientific Corporation (BSX) announced adjusted EPS of 27 cents in the second quarter of 2016, up 22.7% from the year-ago quarter.
BSX: 24.45 (+0.17), GWPH: 95.94 (+1.62), BAX: 48.53 (+0.51), VASC: 46.60 (+0.73)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 130.85 (-0.29), GWPH: 95.94 (+1.62), BAX: 48.53 (+0.51), VASC: 46.60 (+0.73)
NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.45 (+0.17), ZBH: 130.85 (-0.29), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea
CNW Group - Mon Jul 18, 7:30AM CDT
Medical Cannabis' biggest strength continues to be science as research and development drives sector forward with more consumers opting for marijuana over traditional treatment methods. Investors continue to pour millions of dollars into the newest studies and development of Medical Marijuana Applications as more states push towards legalization.
ABT: 45.34 (+0.59), INSY: 16.02 (+0.37), GWPH: 95.94 (+1.62), PFE: 37.31 (+0.42)
Will AmSurg's Merger with Envision Healthcare Drive Growth?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:08PM CDT
AmSurg (AMSG) recently agreed to merge in an all-stock deal with Envision Healthcare to create one of the largest providers of physician services in the U.S.
AMSG: 72.75 (-2.26), BSX: 24.44 (+0.16), EVHC: 23.82 (-0.77), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
Medtronic's IN.PACT Admiral DCB Wins FDA Nod for 150 mm
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 6:22AM CDT
With Medtronic (MDT)being a major player in the medical devices market, surely the FDA approval will accelerate the demand for its peripheral therapy products.
BSX: 24.44 (+0.16), MDT: 88.17 (+0.54), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
Pfizer Publishes Final Data from Atopic Dermatitis Studies
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:10AM CDT
Pfizer (PFE) announced findings from two pivotal phase III studies on crisaborole for the treatment of patients with mild-to-moderate atopic dermatitis.
GWPH: 95.94 (+1.62), PFE: 37.31 (+0.42), SNY: 42.57 (-0.06), REGN: 434.17 (+9.05)
Geron (GERN) Gets Three Patents for Imetelstat in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:02AM CDT
Geron (GERN) announced that it has received three U.S. patents related to its telomerase inhibitor, imetelstat.
JNJ: 125.48 (+0.25), INVA: 13.05 (+0.18), GWPH: 95.94 (+1.62), GERN: 2.71 (+0.03)
MedTech Tailwinds at a Glance: Which Stocks to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:02PM CDT
MedTech Tailwinds at a Glance: Which Stocks to Buy?
ABMD: 119.11 (+1.14), LDRH: 36.98 (-0.02), MDT: 88.17 (+0.54), PAHC: 20.91 (+0.28), MLAB: 115.01 (-0.62), NUVA: 63.39 (+1.19), BSX: 24.44 (+0.16), BABY: 39.29 (-0.04), SNN: 33.16 (-0.13), JNJ: 125.48 (+0.25), DXCM: 92.46 (+0.23), GWPH: 95.94 (+1.62), RMD: 70.03 (+1.15), WOOF: 70.51 (-0.83), ABT: 45.34 (+0.59), VIVO: 19.58 (+0.22), MASI: 53.07 (+0.10), TMO: 159.64 (+0.80), CYH: 12.58 (-0.19), HTWR: 57.93 (-0.01), FEIC: 106.58 (+0.16), ISRG: 695.16 (-0.60), CFMS: 7.00 (+0.03), STE: 71.51 (+0.56), STJ: 83.66 (+0.62), XRAY: 64.20 (+0.16), HOLX: 39.00 (+0.51)
Illumina (ILMN) Rallies on Exact Sciences Buyout Rumor
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:53AM CDT
With this buyout, Illumina (ILMN) will gain control over Cologuard -- a FDA approved non-invasive screening test of Exact Sciences that uses stool DNA technology to detect colorectal cancer.
NXTM: 22.09 (-0.02), GWPH: 95.94 (+1.62), TGTX: 5.77 (-0.14), ILMN: 170.73 (+4.38)
Wall Street Targets Funding Opportunities for Multi-Billion Dollar Cannabis & Legal Marijuana Operations
PR Newswire - Wed Jul 13, 7:45AM CDT
It is estimated that the expense to start a legal marijuana business in the U.S. could cost more than $1Million, according to the Marijuana Business Association. The absence of commercial credit available for the industry in past has opened up opportunities for institutions & private lenders who want to step into the cannabis industry with the average loan estimated at $750,000. Microsoft Corp. (NASDAQ: MSFT) recently became the first major company to announce its participation in the cannabis/marijuana sector, as the computer giant has partnered with Kind Financial, which helps businesses and government agencies track sales of legalized marijuana.
GWPH: 95.94 (+1.62), MSFT: 56.33 (-0.35)
Boston Scientific's Restructuring Plan & Innovation Offer Hope
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:30AM CDT
On Jul 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 24.44 (+0.16), NXTM: 22.09 (-0.02), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
CytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:07AM CDT
CytRx (CYTR) announced unfavorable initial results from a phase III study on aldoxorubicin in patients with relapsed or refractory soft tissue sarcomas.
MACK: 5.86 (+0.06), INVA: 13.05 (+0.18), GWPH: 95.94 (+1.62), CYTR: 0.60 (-0.05)
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Raising $252.0 Million on NASDAQ Global Market
GlobeNewswire - Tue Jul 12, 10:24PM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW" or the "Company"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,800,000 of American Depositary Shares ("ADSs", representing 33,600,000 ordinary shares of GW, at a price to the public of $90.00 per ADS on the NASDAQ Global Market, raising gross proceeds of approximately $252,000,000 (before deducting underwriting discounts, commissions and offering expenses). GW has granted the underwriters a 30-day option to purchase up to an additional 420,000 ADSs at the public offering price less underwriting discounts and commissions. Closing of the offering is expected to occur on July 18, 2016. GWPH: 95.94 (+1.62), MS: 28.53 (-0.20)
FDA Okays Medtronic's NuVent for Expanded Use in Sinusitis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:17PM CDT
Medtronic's (MDT) NuVent is a unique balloon sinus dilation system, which enables a better view of one's sinus anatomy and the optimal placement of balloons during surgery.
NXTM: 22.09 (-0.02), MDT: 88.17 (+0.54), GWPH: 95.94 (+1.62), TGTX: 5.77 (-0.14)
AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:19AM CDT
AbbVie's (ABBV) ABT-414 has been granted Rare Pediatric Disease Designation in the U.S. for the treatment of pediatric patients with EGFR-amplified DIPG.
INVA: 13.05 (+0.18), GWPH: 95.94 (+1.62), SGEN: 49.12 (+1.06), ABBV: 66.97 (+0.74)
Genomic Health to Offer Epic Science's AR-V7 test, Shares Up
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:28AM CDT
The availability of the AR-V7 serves as a further development to Genomic Health's (GHDX) recently launched Oncotype SEQ Liquid Select, a next-generation, liquid biopsy test.
ICUI: 117.68 (+0.92), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19), GHDX: 30.22 (+1.19)
Walgreen Boots: Q3 a Mixed Bag, Achieves $1B in Synergy
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:09AM CDT
In Jun 2016, Walgreens Boots (WBA) was successful in achieving its target of at least $1 billion in combined net synergies from the Alliance Boots deal in fiscal 2016.
ICUI: 117.68 (+0.92), WBA: 79.25 (unch), GWPH: 95.94 (+1.62), NUVA: 63.39 (+1.19)
Why the Earnings Streak Will Continue for GW Pharmaceuticals (GWPH)
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 7:37AM CDT
GW Pharmaceuticals (GWPH) currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
GWPH: 95.94 (+1.62)
